Around the start of the year, American entrepreneur Mark Cuban made headlines when he launched an online pharmacy to deliver generic drugs, and insulins were at the top of the list of therapies that needed alternative cost-effective delivery options. More recently, Civica Rx also announced plans to distribute low-cost biosimilar insulins. In this issue, we take a look at whether e-commerce approaches can truly improve access in a cost-sensitive environment.

The pandemic altered the healthcare space in myriad ways and the boost it gave the cannabis industry presents a particularly interesting case study. Global legal cannabis sales in 2020 were up by 45% on 2019. But there’s a lot more behind this growth, as investigated by one of the features this month.

We also continue our coverage of the evolving situation with the crisis in Ukraine, by taking a look at which trade sectors are most likely to be disrupted, and how big pharma is gradually slowing down its clinical trial operations in Russia.

Also, don’t miss our data-led analysis that identifies some of the least and most equitable employers in the pharma industry when it comes to the gender wage gap in Britain.

All this, and the latest pharma industry news, comment, data and analysis from GlobalData.

Manasi Vaidya, editor

Go to article: Home | Tackling insulin prices Go to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: CommentGo to article: Why did the cannabis industry blossom during the pandemic?Go to article: Negative AdCom vote for Amylyx’s ALS drug AMX0035, but hope remainsGo to article: Will Russia’s invasion affect biopharmaceutical licensing agreements?Go to article: Fall from grace? What 2022 may have in stock for biopharmaceutical SPACsGo to article: BEA TechnologiesGo to article: In DepthGo to article: Insulin pricing: could an e-commerce approach cut costs?Go to article: Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs Go to article: Big pharma’s gradual retreat on clinical trials in Russia Go to article: Covid-19, flu combo vaccines an advance but with rollout quandariesGo to article: FDA shows unease about marketing approval applications based on single-country tGo to article: In DataGo to article: How big is the gender pay gap in the pharma industry in Britain?Go to article: Where is trade most likely to be disrupted in pharma from the Russian invasion oGo to article: Big data innovation among pharma companies dropped off in the last quarterGo to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue